MC
MCRB.US Seres Therapeutics Inc
- Market cap
- USD 14.3M
- P/E
- -
- P/B
- 0.67x
- ROE
- -197.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MCRB.US undervalued?
Graham numberThe Graham number of Seres Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Seres Therapeutics Inc fundamental analysis
No fundamental analysis for Seres Therapeutics Inc yet.
Seres Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also dev…
Full company profileSeres Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Seres Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 21.8M | 32.1M | 28.3M | 34.5M | 33.2M | 145M | 7.13M | 126M | 0.00 | 789K | 2.25M |
| Gross Profit | -60.2M | -57.4M | 28.3M | 34.5M | -57.4M | 145M | 6.12M | -19.3M | -3.53M | -3.34M | 1.61M |
| Operating Income | -92.8M | -91.4M | -100M | -71.9M | -88.1M | -64.5M | -180M | -195M | -121M | -94.0M | -70.2M |
| EBITDA | -88.6M | -82.1M | -92.4M | -62.2M | -79.6M | -56.7M | -171M | -181M | -120M | 9.83M | -66.3M |
| Net Income | -91.6M | -89.4M | -98.9M | -70.3M | -89.1M | -65.6M | -250M | -114M | -147M | 5.70M | -42.2M |
| EPS | -46 | -44 | -49 | -25 | -22 | -14 | -46 | -18 | -19 | 0.64 | -4.22 |
| Balance Sheet | |||||||||||
| Total Assets | 273M | 190M | 120M | 132M | 343M | 355M | 349M | 359M | 140M | 138M | 65.9M |
| Total Liabilities | 140M | 129M | 169M | 181M | 168M | 223M | 338M | 403M | 126M | 94.0M | 44.5M |
| Shareholders' Equity | 133M | 60.7M | -48.0M | -48.3M | 175M | 132M | 10.8M | -44.9M | 13.8M | 44.2M | 21.4M |
| Cash & Short-term Investments | 193M | 150M | 85.8M | 94.8M | 254M | 291M | 181M | 128M | 30.8M | 45.8M | 17.5M |
| Total Debt | 10.7M | 8.99M | 7.25M | 44.8M | 40.8M | 49.2M | 163M | 199M | 91.6M | 83.0M | 35.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 43.9M | -75.5M | -62.9M | -76.5M | -93.6M | 6.69M | -229M | -117M | -149M | 1.12M | -65.6M |
| Capital Expenditure | 21.5M | 4.68M | 1.94M | 1.00M | 591K | 9.57M | 9.82M | 7.98M | 380K | 252K | 18.7K |
| Free Cash Flow | 22.4M | -80.2M | -64.8M | -77.5M | -94.2M | -2.88M | -239M | -125M | -149M | 865K | -65.6M |
| Ratios | |||||||||||
| ROE | -69.0% | -147.3% | - | - | -51.0% | -49.9% | -2,319.9% | - | -1,063.3% | 12.9% | -197.4% |
| ROA | -33.6% | -47.2% | -82.1% | -53.1% | -26.0% | -18.5% | -71.7% | -31.7% | -104.8% | 4.1% | -64.0% |
| Net Profit Margin | -420.7% | -278.4% | -350.0% | -203.7% | -268.3% | -45.2% | -3,509.5% | -90.0% | - | 721.9% | -1,874.2% |
| Debt to Equity | 0.08x | 0.15x | - | - | 0.23x | 0.37x | 15.08x | - | 6.65x | 1.88x | 1.67x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Seres Therapeutics Inc dividends
Seres Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Apr 22, 2025.
Who owns Seres Therapeutics Inc
- Insiders 11.20%
- Institutions 22.15%
- Public & others 66.65%
- Shares outstanding 10.2M
- Free float 8.99M
Top funds holding MCRB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 206K | 2.05% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 39.4K | 0.39% | -0.38% | Sep 2026 |
| Abante Quant Value FI | 24.6K | 0.25% | +87.61% | Aug 2026 |
| iShares Micro-Cap ETF | 23.1K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 13.9K | 0.14% | 0.00% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 12.5K | 0.12% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 10.1K | 0.10% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 10.1K | 0.10% | +297.51% | Jun 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 7.30K | 0.07% | 0.00% | Oct 2026 |
| GS Absolute Ret Trkr I Acc EUR Hdg | 5.56K | 0.06% | 0.00% | Aug 2026 |
| Vanguard Balanced Index Inv | 4.39K | 0.04% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 1.98K | 0.02% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 1.69K | 0.02% | 0.00% | Sep 2026 |
| Pacific Select Large-Cap Growth I | 1.43K | 0.01% | 0.00% | Oct 2026 |
| WisdomTree US SmallCap Earnings ETF | 1.26K | 0.01% | 0.00% | Oct 2026 |
| Avantis® U.S. Small Cap Value Instl | 1.18K | 0.01% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 1.00K | 0.01% | 0.00% | Oct 2026 |
Top institutions holding MCRB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Flagship Ventures Management, Inc. | 1.16M | 11.50% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 288K | 2.86% | -2.16% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 172K | 1.71% | +23.44% | Jun 2026 |
| Vontobel Holding Ltd. | 123K | 1.22% | -11.19% | Jun 2026 |
| BlackRock Inc | 111K | 1.10% | +8.80% | Jun 2026 |
| Geode Capital Management, LLC | 80.0K | 0.80% | +6.87% | Jun 2026 |
| Susquehanna International Group, LLP | 58.3K | 0.58% | -44.63% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 48.7K | 0.48% | +22.81% | Jun 2026 |
| State Street Corp | 33.9K | 0.34% | 0.00% | Jun 2026 |
| Lion Point Capital, LP | 31.6K | 0.31% | 0.00% | Jun 2026 |
| Charles Schwab Investment Management Inc | 31.0K | 0.31% | -1.84% | Jun 2026 |
| XTX Topco Ltd | 20.7K | 0.21% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 15.2K | 0.15% | 0.00% | Jun 2026 |
| Northern Trust Corp | 14.8K | 0.15% | 0.00% | Jun 2026 |
| Amvescap Plc. | 13.0K | 0.13% | -10.81% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 12.1K | 0.12% | -44.06% | Jun 2026 |
| Renaissance Technologies Corp | 11.8K | 0.12% | 0.00% | Sep 2026 |
| Citadel Advisors Llc | 10.5K | 0.10% | 0.00% | Jun 2026 |
| SIMPLEX TRADING, LLC | 4.60K | 0.05% | +49.77% | Jun 2026 |
| SBI Securities Co Ltd | 4.18K | 0.04% | +20.10% | Jun 2026 |
Seres Therapeutics Inc company profile
- Company name
- Seres Therapeutics Inc
- Ticker
- MCRB.US
- Exchange
- USA Stocks
- Listed since
- Jun 26, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 66
- Fiscal year end
- December
- Address
- 101 Cambridgepark Drive, Cambridge, MA, United States, 02140
- Phone
- 617 945 9626
- Website
- serestherapeutics.com
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Seres Therapeutics Inc management
2- Mr. Richard N. Kender B.S., M.B.A.Interim CEO & Executive Chair · born 1956
- Dr. Matthew R. Henn Ph.D.President & Chief Scientific Officer · born 1975